SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-011292
Filing Date
2020-05-07
Accepted
2020-05-07 16:20:27
Documents
14
Period of Report
2020-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea121455-8k_nektartherap.htm   iXBRL 8-K 35252
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL R ea121455ex99-1_nektartherap.htm EX-99.1 91354
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2244
  Complete submission text file 0001213900-20-011292.txt   318262

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20200507.xsd EX-101.SCH 3206
5 XBRL LABEL FILE nktr-20200507_lab.xml EX-101.LAB 34581
6 XBRL PRESENTATION FILE nktr-20200507_pre.xml EX-101.PRE 22720
11 EXTRACTED XBRL INSTANCE DOCUMENT ea121455-8k_nektartherap_htm.xml XML 3501
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 20856756
SIC: 2834 Pharmaceutical Preparations